Perla Breccia

Biopharmaceuticals R&D, AstraZeneca
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

The rise and fall of SARM1 base-exchange inhibitors.

The rise and fall of SARM1 base-exchange inhibitors.

Journal: Communications chemistry

Published: December 19, 2025

Topical BET PROTACs for locally restricted protein degradation in the lung.

Topical BET PROTACs for locally restricted protein degradation in the lung.

Journal: RSC medicinal chemistry

Published: February 24, 2025

A molecular stabiliser of an inhibitory eIF2B-eIF2(αP) complex activates the Integrated Stress Response.

A molecular stabiliser of an inhibitory eIF2B-eIF2(αP) complex activates the Integrated Stress Response.

Journal: Nature communications

Published: February 13, 2025

Identification and Optimization of RNA-Splicing Modulators as Huntingtin Protein-Lowering Agents for the Treatment of Huntington's Disease.

Identification and Optimization of RNA-Splicing Modulators as Huntingtin Protein-Lowering Agents for the Treatment of Huntington's Disease.

Journal: Journal of medicinal chemistry

Published: September 15, 2023

Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington's Disease Pathology.

Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington's Disease Pathology.

Journal: Journal of medicinal chemistry

Published: September 13, 2022

Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease.

Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease.

Journal: Journal of medicinal chemistry

Published: March 30, 2021

Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.

Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.

Journal: ACS medicinal chemistry letters

Published: October 12, 2020

Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.

Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.

Journal: Journal of medicinal chemistry

Published: March 07, 2019

Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.

Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.

Journal: Bioorganic & medicinal chemistry letters

Published: August 14, 2018

Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors.

Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors.

Journal: ACS medicinal chemistry letters

Published: July 30, 2015

Inter- and intramolecular annulation strategies to a cyclopentanone building block containing an all-carbon quaternary stereogenic center.

Inter- and intramolecular annulation strategies to a cyclopentanone building block containing an all-carbon quaternary stereogenic center.

Journal: Organic letters

Published: February 28, 2015

Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.

Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.

Journal: Journal of medicinal chemistry

Published: November 23, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026